Next Level Private LLC Buys 2,905 Shares of Bristol-Myers Squibb (NYSE:BMY)

Next Level Private LLC boosted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 72,011 shares of the biopharmaceutical company’s stock after buying an additional 2,905 shares during the quarter. Bristol-Myers Squibb makes up approximately 1.5% of Next Level Private LLC’s portfolio, making the stock its 19th largest holding. Next Level Private LLC’s holdings in Bristol-Myers Squibb were worth $3,726,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. ESL Trust Services LLC bought a new position in Bristol-Myers Squibb during the first quarter worth about $27,000. LGT Financial Advisors LLC boosted its position in Bristol-Myers Squibb by 42.7% during the second quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 227 shares during the period. Fairman Group LLC bought a new position in Bristol-Myers Squibb during the fourth quarter worth about $42,000. Redmont Wealth Advisors LLC bought a new position in Bristol-Myers Squibb during the first quarter worth about $47,000. Finally, Accent Capital Management LLC bought a new position in Bristol-Myers Squibb during the fourth quarter worth about $46,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock opened at $52.19 on Friday. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $57.65. The company has a market capitalization of $105.79 billion, a P/E ratio of -16.84, a PEG ratio of 13.75 and a beta of 0.46. The stock has a 50 day moving average price of $49.75 and a two-hundred day moving average price of $46.43.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. The firm had revenue of $12.20 billion for the quarter, compared to analysts’ expectations of $11.54 billion. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.75 earnings per share. Analysts expect that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be paid a dividend of $0.60 per share. The ex-dividend date is Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.60%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BMY. Barclays increased their price target on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a report on Monday, October 7th. BMO Capital Markets reissued a “market perform” rating and issued a $48.00 price target on shares of Bristol-Myers Squibb in a report on Monday, September 23rd. Jefferies Financial Group increased their price target on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Finally, TD Cowen raised their target price on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $53.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.